Ultragenyx Pharma (RARE) PT Lowered to $70 at Baird; Multiple Milestones Ahead
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
February 20, 2018 4:05 PM ESTNOVATO, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter and full year ended December 31, 2017.
2017 was a transformative year for Ultragenyx with our first product approval and launch of Mepsevii, significant clinical and regulatory progress, and the addition of gene therapy development and manufacturing technology through the acquisition of Dimension Therapeutics, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of... More
